The FDA has approved a new drug application for Xelpros to reduce IOP in open-angle glaucoma and ocular hypertension, Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company announced in a joint press release.
Xelpros (latanoprost ophthalmic solution 0.005%) is the first latanoprost product not formulated with the preservative benzalkonium chloride and was developed with SPARC’s Swollen Micelle Microemulsion technology, the release said.
It was shown to reduce IOP in patients with open-angle glaucoma and ocular hypertension up to a mean of 6 mm Hg to 8 mm Hg in randomized
Uncategorized